# A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults

> **NCT07526116** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 64 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** REGN22044
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07526116
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-07
- **Primary completion:** 2027-05-27
- **Final completion:** 2027-05-27
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07526116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07526116, "A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07526116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*